We are live on ! Find out more
SAM

Senzar Asset Management Portfolio holdings

AUM $34.7M
1-Year Est. Return 0.56%
This Fund
S&P 500
This Quarter Est. Return
+12.1%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$341M
AUM Growth
+$160K
Cap. Flow
-$29.8M
Cap. Flow %
-8.73%
Top 10 Hldgs %
53.88%
Holding
39
New
10
Increased
16
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
BHC icon
Bausch Health
BHC
+$20.2M
2
AGN
Allergan plc
AGN
+$17.9M
3
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$11.4M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$10.7M
5
SNY icon
Sanofi
SNY
+$10.5M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$30.7M
2
ABBV icon
AbbVie
ABBV
+$24.9M
3
ENTA icon
Enanta Pharmaceuticals
ENTA
+$23.4M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$18.8M
5
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$17.8M

Sector Composition

Rank Sector Weight
1 Healthcare 85.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNY icon
1
Sanofi
SNY
$105B
$32.2M 9.43%
705,112
+217,012
+44% +$10.5M
VTRS icon
2
Viatris
VTRS
$19.8B
$26.1M 7.65%
463,300
-242,200
-34% -$13M
CYH icon
3
Community Health Systems
CYH
$440M
$23.5M 6.88%
526,471
+145,684
+38% +$6.23M
BHC icon
4
Bausch Health
BHC
$1.75B
$21.5M 6.3%
+150,300
New +$20.2M
AGN
5
DELISTED
Allergan plc
AGN
$18.4M 5.4%
+71,600
New +$17.9M
TEVA icon
6
Teva Pharmaceuticals
TEVA
$36.1B
$13.3M 3.89%
230,897
-337,499
-59% -$18.8M
BIIB icon
7
Biogen
BIIB
$29.5B
$12.8M 3.76%
37,800
+11,000
+41% +$3.56M
MGLN
8
DELISTED
Magellan Health Services, Inc.
MGLN
$12.5M 3.67%
208,500
+200
+0.1% +$11.8K
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$634M
$12M 3.51%
+933,469
New +$10.7M
CNCE
10
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$11.5M 3.38%
866,200
+605,000
+232% +$7.81M
CNMD icon
11
CONMED
CNMD
$1.31B
$11.2M 3.28%
248,900
-11,500
-4% -$482K
COV
12
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$10.8M 3.17%
105,862
-185,638
-64% -$17.8M
INSM icon
13
Insmed
INSM
$23.2B
$10.5M 3.07%
677,600
+14,300
+2% +$203K
SLXP
14
DELISTED
SALIX PHARMACEUTICALS LTD DEL
SLXP
$9.82M 2.88%
+85,400
New +$10.3M
ICPT
15
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$9.66M 2.83%
+61,900
New +$11.4M
XNPT
16
DELISTED
XENOPORT, INC.
XNPT
$9.55M 2.8%
1,088,700
-246,600
-18% -$1.81M
OFIX icon
17
Orthofix Medical
OFIX
$467M
$9.22M 2.7%
306,898
+5,300
+2% +$155K
FPRX
18
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$8.98M 2.63%
332,474
+34,174
+11% +$588K
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$8.22M 2.41%
+212,503
New +$6.69M
MDVN
20
DELISTED
MEDIVATION, INC.
MDVN
$7.92M 2.32%
+159,000
New +$8.27M
TVTX icon
21
Travere Therapeutics
TVTX
$5.16B
$7.78M 2.28%
635,700
+343,300
+117% +$3.55M
RPRX
22
DELISTED
Repros Therapeutics Inc.
RPRX
$7.62M 2.23%
764,406
+10,806
+1% +$92.2K
MNTA
23
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$7.03M 2.06%
583,716
+129,116
+28% +$1.48M
SGNT
24
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
$6.74M 1.97%
268,300
+113,400
+73% +$3.33M
CORI
25
DELISTED
Corium International, Inc.
CORI
$6.18M 1.81%
1,012,420
+453,600
+81% +$2.58M
1
2

Similar funds

BCP
Blum Capital Partners San Francisco, California $34.1M AUM 1.14% 1-Year Est. Return
PRHC
P.R. Herzig & Co Roslyn Heights, New York $45.9M AUM 15.88% 1-Year Est. Return
NAM
Needelman Asset Management Ladera Ranch, California $46M AUM 8.27% 1-Year Est. Return
GG
Gores Group Beverly Hills, California $22.3M AUM 4.58% 1-Year Est. Return
SM
SLS Management New York $17.2M AUM 14.82% 1-Year Est. Return
BC
Breogan Capital New York $56.4M AUM
SCPM
Social Capital PEP Management Palo Alto, California $56.5M AUM
FAM
Fortaleza Asset Management Chicago, Illinois $12.3M AUM 48.33% 1-Year Est. Return

Senzar Asset Management's Q4 2014 Portfolio in Review

As of Q4 2014, Senzar Asset Management held 39 positions worth $341M, up 0.05% from $341M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Senzar Asset Management withdrew a net $29.8M in Q4 2014, closing 7 positions and reducing 6 holdings. Its most notable exit was GSK, an estimated $30.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier.

Against the trend, Senzar Asset Management opened a new position in Bausch Health worth $21.5M.

  • Senzar Asset Management's largest Q4 2014 buy was Bausch Health: 150,300 shares worth $21.5M.
  • Senzar Asset Management added most to Sanofi in Q4 2014, an estimated $10.5M increase.
  • Senzar Asset Management's biggest Q4 2014 reduction was Enanta Pharmaceuticals, cutting an estimated $23.4M.
  • Senzar Asset Management fully exited GSK in Q4 2014, selling an estimated $30.7M.
  • Senzar Asset Management's ten largest holdings make up 54% of its $341M portfolio in Q4 2014.
  • Senzar Asset Management opened 10 new positions and closed 7 in Q4 2014.
  • Senzar Asset Management's portfolio value rose 0.05% quarter-over-quarter to $341M.

Based on Senzar Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.